359 related articles for article (PubMed ID: 23926207)
1. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
Hata J; Arima H; Rothwell PM; Woodward M; Zoungas S; Anderson C; Patel A; Neal B; Glasziou P; Hamet P; Mancia G; Poulter N; Williams B; Macmahon S; Chalmers J;
Circulation; 2013 Sep; 128(12):1325-34. PubMed ID: 23926207
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Variability in Systolic Blood Pressure Related to Vascular Events and Premature Death in Type 2 Diabetes Mellitus: The ADVANCE-ON Study.
Ohkuma T; Woodward M; Jun M; Muntner P; Hata J; Colagiuri S; Harrap S; Mancia G; Poulter N; Williams B; Rothwell P; Chalmers J;
Hypertension; 2017 Aug; 70(2):461-468. PubMed ID: 28584014
[TBL] [Abstract][Full Text] [Related]
3. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
5. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Patel A; ; MacMahon S; Chalmers J; Neal B; Woodward M; Billot L; Harrap S; Poulter N; Marre M; Cooper M; Glasziou P; Grobbee DE; Hamet P; Heller S; Liu LS; Mancia G; Mogensen CE; Pan CY; Rodgers A; Williams B
Lancet; 2007 Sep; 370(9590):829-40. PubMed ID: 17765963
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
Cardoso CRL; Leite NC; Salles GF
Cardiovasc Diabetol; 2020 May; 19(1):50. PubMed ID: 32359350
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes.
Ilkun OL; Greene T; Cheung AK; Whelton PK; Wei G; Boucher RE; Ambrosius W; Chertow GM; Beddhu S
Diabetes Care; 2020 Aug; 43(8):1878-1884. PubMed ID: 32366577
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
[TBL] [Abstract][Full Text] [Related]
11. Visit-to-visit variability of blood pressure and risk of macrovascular and microvascular complications in patients with type 2 diabetes: A Chinese primary-care cohort study.
Deng Y; Liu Y; Zhang S; Yu H; Zeng X; An R; Chen Z; Sun N; Yin X; Dong Y
J Diabetes; 2022 Nov; 14(11):767-779. PubMed ID: 36443961
[TBL] [Abstract][Full Text] [Related]
12. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes.
Zoungas S; Woodward M; Li Q; Cooper ME; Hamet P; Harrap S; Heller S; Marre M; Patel A; Poulter N; Williams B; Chalmers J;
Diabetologia; 2014 Dec; 57(12):2465-74. PubMed ID: 25226881
[TBL] [Abstract][Full Text] [Related]
13. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus.
Hillis GS; Hata J; Woodward M; Perkovic V; Arima H; Chow CK; Zoungas S; Patel A; Poulter NR; Mancia G; Williams B; Chalmers J
J Am Heart Assoc; 2012 Oct; 1(5):e002832. PubMed ID: 23316296
[TBL] [Abstract][Full Text] [Related]
14. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.
Mohammedi K; Woodward M; Hirakawa Y; Zoungas S; Colagiuri S; Hamet P; Harrap S; Poulter N; Matthews DR; Marre M; Chalmers J;
Cardiovasc Diabetol; 2016 Sep; 15(1):129. PubMed ID: 27590190
[TBL] [Abstract][Full Text] [Related]
15. China Stroke Primary Prevention Trial: Visit-to-Visit Systolic Blood Pressure Variability Is an Independent Predictor of Primary Stroke in Hypertensive Patients.
Men X; Sun W; Fan F; Zhao M; Huang X; Wang Y; Liu L; Liu R; Sun W; Peng Q; Qin X; Tang G; Li J; Zhang Y; Cai Y; Hou FF; Wang B; Xu X; Cheng X; Sun N; Huang Y; Huo Y
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28288974
[TBL] [Abstract][Full Text] [Related]
16. Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial.
Hata J; Arima H; Zoungas S; Fulcher G; Pollock C; Adams M; Watson J; Joshi R; Kengne AP; Ninomiya T; Anderson C; Woodward M; Patel A; Mancia G; Poulter N; MacMahon S; Chalmers J; Neal B;
PLoS One; 2013; 8(2):e55807. PubMed ID: 23390553
[TBL] [Abstract][Full Text] [Related]
17. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.
Zoungas S; Chalmers J; Ninomiya T; Li Q; Cooper ME; Colagiuri S; Fulcher G; de Galan BE; Harrap S; Hamet P; Heller S; MacMahon S; Marre M; Poulter N; Travert F; Patel A; Neal B; Woodward M;
Diabetologia; 2012 Mar; 55(3):636-43. PubMed ID: 22186981
[TBL] [Abstract][Full Text] [Related]
18. ADVANCE: action in diabetes and vascular disease.
Patel A; Chalmers J; Poulter N
J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
[TBL] [Abstract][Full Text] [Related]
19. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
ADVANCE Management Committee
Diabetologia; 2001 Sep; 44(9):1118-20. PubMed ID: 11596665
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes.
Harris K; Muntner P; Woodward M; Jun M; Oshima M; Gong J; Harrap S; Menard J; Chalmers J
J Hum Hypertens; 2023 Mar; 37(3):181-188. PubMed ID: 35184142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
